deletions | additions       diff --git a/Method.tex b/Method.tex  index 0ebe337..8940964 100644  --- a/Method.tex  +++ b/Method.tex 
...
\subsection{Sample preparation}  ***This subsection needs to be checked (+Eylea).***  ***should we not also mention the labelled IgG and BSA here?***  Ranibizumab and bevacizumab solutions were dialysed twice against phosphate buffered saline (PBS) (PBS,  pH 7.4 7.4)  using D-Tube Midi Dialyzer units from Novagen (6-8~kD cut-off). with a 6-8kD cut-off (Novagen).  Subsequently, the purity of the dialysed proteins was checked by standard SDS-PAGE. SDS-PAGE and confirmed to correspond to the manufacturer's purity values for the proteins.  The proteins were then conjugated to the fluorophore Bis(2,2′-bipyridine)-4′-methyl-4-carboxybipyridine-ruthenium bis(hexafluorophosphate) (synonym, N-succinimidyl ester-Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2)(Sigma-Aldrich) by using a succinimidyl N-succinimidyl  ester-modified fluorophore (NHS-fluorophore)  with a short linker (Invitrogen, F6130). Conjugation reactions were performed in PBS adjusted with 1M  bicine buffer to pH 8.6 at 2~mg/ml 2mg/ml  protein concentration in the dark at room temperature  with the activated fluorophore ester NHS-fluorophore  being used in at 2-fold molar  excess. The reaction was stopped after two hours 2.5h  and conjugated proteins were separated from remaining free dye by size exclusion chromatography (7~kD (Zeba(R) spin columns with a 7kD  cut-off; Thermo Fisher). Using this method we generated ranibizumab conjugated to dye with a dye:protein ratio of 1.1:1 and bevacizumab with a dye:protein ratio of 1.3:1. Azide (2.0~mM) Sodium azide  was added to all fluorophore-conjugated drugs at a final concentration of 2.0mM  to protect them the protein solution  from any  microbial deterioration. \subsection{Tr-FAIM measurements}